#AIEye
#Podcast 695: #Stocks discussed: (ASX:BRN) (TSX: $DTOL.TO) #artificialintelligence
BrainChip
Partners with Edge Impulse, and D2L Expands Use of AI Tech
Global
#AI in #Pharma to Reach $7.14B by 2029
Vancouver, Kelowna, Delta, BC – May 16, 2022 – Investorideas.com,
a global investor news source covering Artificial Intelligence (AI) brings
you today’s edition of The
AI Eye-watching stock news, deal tracker and advancements in
artificial intelligence.
Listen
to today’s podcast:
https://www.investorideas.com/Audio/Podcasts/2022/051622-AI-Eye.mp3
Read
this in full at https://www.investorideas.com/news/2022/artificial-intelligence/05161BRN-DTOL.asp
Today’s
Column- The
AI Eye- Watching stock news, deal tracker and advancements
in artificial intelligence
Stocks
discussed: (ASX:BRN) (TSX:DTOL)
BrainChip Holdings Ltd. (ASX:BRN) and Edge Impulse, a development
platform for machine learning (ML) on edge devices, are partnering to deliver next-generation
platforms to customers looking to develop products utilizing the companies'
machine learning capabilities. Jerome Nadel, BrainChip’s CMO, said:
"Partnering
with Edge Impulse creates a unique market solution that brings their powerful
and easy to use AI/ML application design platform unparalleled performance with
BrainChip's silicon proven on-chip learning and ultra-low power IP. We continue
to look for partnerships that will advance opportunities to enable a wide array
of edge AI capabilities, such as continuous learning and real-time inference.
Edge Impulse is a perfect addition to our ecosystem of providers enabling
next-generation technology to markets around the world."
Global learning technology company D2L Inc. (TSX:DTOL) has announced an expansion in its use of
intelligent technology, including artificial intelligence, smart workflow
design, and automation, to “help educators personalize learning.” John Baker,
President and CEO of D2L, said:
“For
more than a decade, D2L has been at the forefront of building intelligent tools
within our products to make it easier to build engaging experiences and get the
right feedback to learners when they need it the most. Personalizing learning
is not easy, and our goal with intelligent tools is to help instructors save time,
so they can focus on what really matters: improving outcomes for their
learners.”
Global
AI in Pharma to Reach $7.14B by 2029
A report published by Polaris Market Research finds that the global
AI in Pharmaceutical market is projected to grow from $859.1 million USD in
2021 to $7.14 billion in 2029, registering a compound annual growth rate (CAGR)
fo 31.2 percent in the forecast period 2022-29. The following excerpt from the
report’s description outlines the ways in which AI is being leveraged in the
market:
Drug
discovery, smart manufacturing, automated control processes systems, the
prediction of new treatments, and the production of novel peptides from natural
foods raise awareness for the use of AI in pharma.
Furthermore,
pharma companies present across the global market are using advanced machine
learning algorithms and AI-powered tools to speed up the drug discovery
process. These technologies are designed to detect complex patterns in vast
datasets and may thus solve problems related to complex biological networks.
Sam Mowers, Investorideas.com
Read and
hear other editions of the AI Eye
For a list of
artificial intelligence stocks on Investorideas.com visit
here
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
publishes breaking stock news, third party stock research, guest posts and
original articles and podcasts in leading stock sectors. Learn about investing in stocks and get
investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy, gaming and more. Investor Idea’s original branded content
includes podcasts and columns : Crypto Corner , Play
by Play sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast ,
Cleantech
and Climate Change , Exploring
Mining , Betting
on Gaming Stocks Podcast and
the AI
Eye Podcast.
The
Investorideas.com podcasts are also available on Apple Podcasts , Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio, Google Podcasts
and most audio platforms available.
Visit the Podcast
page at Investorideas.com: https://www.investorideas.com/Audio/
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions. More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must
adhere to regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
The AI Eye-
Watching stock news, deal tracker and advancements in artificial
intelligence is an original content brand of Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact
Investorideas.com
800 665 0411
Get more Technology stock investor
ideas - news, articles, podcasts and stock directories
No comments:
Post a Comment